Drug Profile
Research programme: folate receptor alpha-targeted vaccines - VaxOnco/Mayo Clinic
Alternative Names: Breast/ovarian cancer vaccine - VaxOnco; FOLR-alpha vaccine; FR-alpha vaccineLatest Information Update: 27 Mar 2014
Price :
$50
*
At a glance
- Originator Mayo Clinic; VaxOnco
- Class
- Mechanism of Action Folate receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer
Most Recent Events
- 26 Mar 2014 No development reported - Preclinical for Breast cancer in USA (unspecified route)
- 26 Mar 2014 No development reported - Preclinical for Ovarian cancer in USA (unspecified route)
- 28 Jul 2011 Preclinical trials in Breast cancer in USA (unspecified route)